Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $3.8 million.

  • Myriad Genetics' Interest Expenses rose 37500.0% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 12666.67%. This contributed to the annual value of $2.8 million for FY2024, which is 344.83% down from last year.
  • As of Q3 2025, Myriad Genetics' Interest Expenses stood at $3.8 million, which was up 37500.0% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Interest Expenses ranged from a high of $3.8 million in Q3 2025 and a low of $500000.0 during Q4 2021
  • In the last 5 years, Myriad Genetics' Interest Expenses had a median value of $800000.0 in 2022 and averaged $1.1 million.
  • Per our database at Business Quant, Myriad Genetics' Interest Expenses tumbled by 9137.93% in 2021 and then surged by 37500.0% in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Interest Expenses stood at $500000.0 in 2021, then soared by 80.0% to $900000.0 in 2022, then changed by 0.0% to $900000.0 in 2023, then decreased by 22.22% to $700000.0 in 2024, then surged by 442.86% to $3.8 million in 2025.
  • Its Interest Expenses stands at $3.8 million for Q3 2025, versus $1.5 million for Q2 2025 and $800000.0 for Q1 2025.